Rubius Therapeutics, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
C/O Verdolino & Lowey, P.C., 124 Washington Street, Suite 101, Foxboro, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-K - Q4 2022 - Feb 27, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 452 % -51.9%
Debt-to-equity 145 % +161%
Return On Equity -255 % -214%
Return On Assets -104 % -99.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.4M shares +0.35%
Common Stock, Shares, Outstanding 90.4M shares +0.36%
Entity Public Float 28.4M USD -96.7%
Common Stock, Value, Issued 90K USD 0%
Weighted Average Number of Shares Outstanding, Basic 90.4M shares +0.62%
Weighted Average Number of Shares Outstanding, Diluted 90.4M shares +0.62%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 96.4M USD -31.9%
General and Administrative Expense 30.8M USD -41.9%
Operating Income (Loss) -178M USD +8.31%
Nonoperating Income (Expense) -1.22M USD +36.8%
Net Income (Loss) Attributable to Parent -180M USD +8.59%
Earnings Per Share, Basic -0.7 USD/shares -27.3%
Earnings Per Share, Diluted -0.7 USD/shares -27.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.9M USD -93.4%
Cash, Cash Equivalents, and Short-term Investments 141M USD
Assets, Current 20.2M USD -91.2%
Property, Plant and Equipment, Net 146K USD -99.7%
Operating Lease, Right-of-Use Asset 2.68M USD -92.4%
Assets 23.1M USD -92.7%
Accounts Payable, Current 1.23M USD -89.4%
Employee-related Liabilities, Current 0 USD -100%
Liabilities, Current 7.94M USD -77.1%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 7.94M USD -94.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -122K USD -12300%
Retained Earnings (Accumulated Deficit) -857M USD -26.5%
Stockholders' Equity Attributable to Parent 15.1M USD -91.5%
Liabilities and Equity 23.1M USD -92.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -47.1M USD -21.7%
Net Cash Provided by (Used in) Investing Activities -80.8M USD -294%
Common Stock, Shares Authorized 300M shares +100%
Common Stock, Shares, Issued 90.4M shares +0.36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -128M USD -165%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.9M USD -93.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.43M USD +35.2%
Deferred Tax Assets, Valuation Allowance 263M USD +27.4%
Deferred Tax Assets, Gross 264M USD +21.3%
Operating Lease, Liability 1.1M USD -97.1%
Payments to Acquire Property, Plant, and Equipment 2.4M USD +221%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -180M USD +8.59%
Lessee, Operating Lease, Liability, to be Paid 1.1M USD -97.6%
Property, Plant and Equipment, Gross 570K USD -99.2%
Operating Lease, Liability, Current 1.1M USD -87.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.1M USD -87.8%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -105%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 160M USD +9.39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Operating Lease, Payments 1.82M USD -4.1%
Additional Paid in Capital 872M USD +1.87%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.56M USD +4.21%
Share-based Payment Arrangement, Expense 15.8M USD -55.7%
Interest Expense 3.86M USD -40%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%